 Novo Nordisk has suspended one of its employees after the employee yesterday was charged by the Danish Public Prosecutor for Serious Economic Crime with unlawful insider trading in the company's shares.
The employee does not have managerial responsibility, but has had access to information, which may influence Novo Nordisk's share price.
Novo Nordisk is cooperating with the public prosecutor in the investigation of the matter, which according to the information available today is believed to be an isolated case involving a single employee.
As the preliminary investigations indicate a serious violation of Novo Nordisk's internal rules regarding trading in the company's shares, the employee has been suspended with immediate effect.
As per agreement with the office of the Danish Public Prosecutor, no further details on the matter can be released at this point in time.
About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com. |
news
European Commission - Pharmaceuticals
US Food and Drug Administration 
